Buy & Sell Estee Lauder Companies Inc (EL) – Estee Lauder Companies Inc Price Today
Aura AI Summary
Key Stats
- $29.04BMarket Cap
- Consumer StaplesSector
- -41.69%3M Drawdown
- $35.22BEnterprise Value
- 1.74%Dividend Yield
- 118 daysTypical Hold Time
Estee Lauder Companies Inc (EL) is currently valued at a market capitalization of $29.04B, with an enterprise value of $35.22B. Over the past 52 weeks, Estee Lauder Companies Inc has traded between a low of $63.66 and a high of $119.61, highlighting its annual price range. Over the past three months, Estee Lauder Companies Inc has recorded a drawdown of -41.69%, reflecting recent price volatility. Estee Lauder Companies Inc offers a dividend yield of 1.74%, with the most recent dividend of $0.35 paid on 27 Feb 26. On average, investors hold Estee Lauder Companies Inc for approximately 118 days, indicating typical investor behavior on the platform.
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Most Recent News
IREN acquires Awaken to boost global brand and marketing strategy amid expansion.
IREN Limited has acquired Awaken, a creative and media agency, to strengthen its brand awareness and marketing as it expands globally. Awaken, previously IREN's external marketing partner, will now operate in-house with key team members, including CE...
Sitryx Therapeutics to present at major healthcare investor conferences in June 2026
Sitryx Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, announced its management will participate in three key investor conferences in June 2026: Jefferies Global Healthcare Conference in New Y...
Regeneron shares drop 10% after Phase 3 melanoma trial misses primary endpoint.
Regeneron Pharmaceuticals' stock fell over 10% following the Phase 3 trial results for their melanoma treatment combining fianlimab and cemiplimab. The trial did not achieve statistical significance for the primary endpoint of progression-free surviv...
